Efficacy of prophylactic single-dose therapy using fluoroquinolone  for prostate brachytherapy.
OBJECTIVE
There is little definitive evidence to guide the use of prophylactic antibiotics for prostate brachytherapy. The purpose of this study is to evaluate the incidence of postimplant infections in patients who receive antimicrobial prophylaxis with pazufloxacin (PZFX).


METHODS
A total of 84 patients who underwent prostate brachytherapy received a single intravenous dose of PZFX at 500 mg perioperatively for 1 day. No postimplant antibiotic medication was prescribed. Urinalysis, plasma white blood cell (WBC) count, and C reactive protein (CRP) levels were evaluated before the implantation, on the day after implantation, and on the 7th and 28th days after brachytherapy.


RESULTS
None of the 84 patients (0.0%) developed a symptomatic urinary tract infection or had febrile infectious complications after brachytherapy. There were statistically significant elevations in the levels of erythrocytes, leukocytes, bacteria in urine, plasma WBC and CRP postoperatively, but these values did not exceed the normal range or were only slightly elevated on the day after brachytherapy (day 1) and on day 7. All laboratory examinations had returned to the normal range on day 28.


CONCLUSIONS
Single-dose therapy with fluoroquinolone helps to prevent infections after prostate brachytherapy.
Department of Urology, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita 879-5593, Japan. TAKE@oita-u.ac.jp
Takeo
T
Nomura
Kenichi
K
Hirai
Mutsushi
M
Yamasaki
Toru
T
Inoue
Mika
M
Takahashi
Takayuki
T
Kawashima
Fuminori
F
Sato
Hiromitsu
H
Mimata
D000368:Aged; D019072:Antibiotic Prophylaxis; D001918:Brachytherapy / Q000009:adverse effects*; D024841:Fluoroquinolones / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000008:administration & dosage*; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D016896:Treatment Outcome
D024841:Fluoroquinolones; D010078:Oxazines; C078052:pazufloxacin